2Colombo A,Latib A.Treatment of drug-eluting stent restenosis with another drug-eluting stent:do not fail the second time[J].Rev Esp Cardiol,2008,61:1120-1122.
3Joner M,Finn AV,Farb A,et al.Pathology of drug-eluting stents in humans delayed healing and late thrombotic risk[J].J Am Coll Cardiol,2006,48(1):193-202.
4Tsimikas S.Drug-eluting stents and late adverse clinical outcomes:lessons learned,lessons awaited[J].J Am Coll Cardiol,2006,47 (10):2112 -2115.
5Nebeker JR,Vimani R,Bennett CL,et al.Hypersensitivity cases associated with drug-eluting coronary stents:a review of available cases from the Research on Adverse Drug Events and Reports[RADAR]project[J].J Am Coll Cardiol,2006,47 (1):175-181.
6Ernst NM,Suryapranata H,Miedema K,et al.Achieved platelet aggregation inhibition after different antiplatelet regimens during percutaneous coronary intervention for ST-segment elevation myocardial infarction[J].J Am Coll Cardiol,2004,44 (6):1187-1193.
7Eikelboom JW,Hirsh J,Weitz JI,et al.Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction,stroke,or cardiovascular death in patients at high risk for cardiovascular events[J].Circulation,2002,105:1650-1655.
8de Caterina R,Giannessi D,Bernini W,et al.Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction[J].Am J Cardiol,1985,55(5):589-590.
9Clarke RJ,Mayo G,Price P,et al.Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin[J].N Engl J Med,1991,325(16):1137-1141.
10Roderick PJ,Wilkes HC,Meade TW.The gastrointestinal toxicity of aspirin:an overview of randomised controlled trials[J].Br J Clin Pharmacol,1993,35(3):219-226.
